Also, as CSF biomarker analysis can be carried out with automated chemiluminescent platforms with high reproducibility and minimal effort, CSF biomarkers like amyloid β-peptide (Aβ)42/Aβ40, p-181-tau, and total tau have been used to identify AD independent of the clinical-stage (Jack Jr et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.